IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to invest in. On February 3, BTIG lowered its price target on IDEXX Laboratories Inc. (NASDAQ:IDXX) to $800 from $830 and maintained a Buy rating. The firm cited concerns about IDEXX’s 2026 guidance despite robust Q4 2025 earnings performance.
IDEXX reported strong fourth-quarter results, with revenue of $1.09 billion, up 14% from last year and above analyst expectations of $1.072 billion. Earnings per share rose 18% to $3.08, beating the Street’s $2.93 estimate. The company remains highly profitable, with a 61.7% gross margin and a return on equity of 65% over the past 12 months.
The companion animal business, IDEXX’s core segment, grew 15% to $998 million, driven by strong instrument revenue of $58 million, up 76% year-over-year. Growth was supported by 1,940 InVueDx system placements, as well as strong demand for Catalyst and SediVue products. This continues IDEXX’s long-term trend of about 10% annual revenue growth and aligns with management’s strategy of share buybacks to boost shareholder value.
For 2026, IDEXX expects revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, with operating margins slightly improving to 32%–32.5%. BTIG noted a 200-basis-point drag from fewer pet visits, mainly from lower-income owners, but expects 4% price growth globally. The company also plans around 5,500 new InVueDx system placements next year, compared with 6,400 in 2025, to help offset these headwinds.
IDEXX Laboratories Inc. (NASDAQ:IDXX) develops, manufactures, and distributes diagnostic and information technology products for veterinary, livestock, poultry, dairy, and water testing markets. Its offerings include point-of-care diagnostic instruments, rapid assay test kits, veterinary reference laboratory services, and microbiological contaminant testing systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Following Samsung, will TSMC raise prices by 10-15% across all process nodes?
The surge in AI demand has led to a severe shortage of advanced production capacity at TSMC, with N2 and N3 nodes almost fully booked by Apple and NVIDIA. Following Samsung's move in July to raise 4nm and 5nm process prices by 10–15%, TSMC plans to follow suit, with N3 already increasing by 15%. Prices for N2 and N5 will rise another 5–10% by early 2027 at the latest, and mature nodes such as N12, N16, and N28 will also see hikes of up to 10%. Strong pricing power has prompted Wall Street to significantly raise its earnings forecasts and target prices for the company.
Jackson Hole shows fissures: The U.S. sells euros and buys yen without prior notice; the European Central Bank fears USD swap lines could "disappear overnight"
This incident reveals that the norms of transatlantic financial cooperation are on the brink of collapse. The United States' unconventional unilateral financial actions have triggered deep anxiety in Europe: the political intervention by the Trump administration is disregarding the interests of its allies and could even weaponize the very foundation of global financial stability. Despite the Federal Reserve’s efforts to reassure, it can no longer guarantee against the unpredictability of the U.S. executive branch, severely damaging mutual trust between Europe and America.
Following Samsung, will TSMC raise prices for all processes by 10~15%?
Analysts say Shiba Inu could erase a zero if Bitcoin reaches $100,000
Crypto prices
More
